HARRI JARVELAINEN, D.V.M., Ph.D., COO
Dr. Jarvelainen has more than 20 years of diverse scientific, managerial and executive experience, including 15 years in pharmaceutical industry – covering the development of small molecules and biologicals from discovery to early development in multiple therapeutic areas. He has contributed to more than 30 first-in-man projects and has worked with more than 50 biotechnology companies over the years, providing scientific, regulatory and strategic advice. Most of his big pharma experience is from AstraZeneca, where his work involved portfolio and program management in Respiratory / Inflammation (Lund, Sweden) and CNS / Pain research areas (Montreal, Canada), as well as global due diligence and external research activities. Previously, he also served as Vice President at Pharmaron, where he oversaw toxicology and program management operations for the company. Dr. Jarvelainen received his Veterinary Medicine and PhD degrees at University of Helsinki and undertook postdoctoral training at New York University Medical Center and Max Planck Institute. He is an author on over 30 peer-reviewed scientific publications and has served as Adjunct Professor of Toxicology at University of Helsinki since 2004.